On January 9th, Merck announced that its nine valent human papillomavirus vaccine (brewing yeast) (trade name: Jiada Xiu® 9) has been approved by the National Medical Products Administration of China for the second dose vaccination program (0, June December) for women aged 9-14 years old. This approval means that on the basis of the three dose vaccination program for the previous 9-45 years old, Jiada Xiu& Reg; 9 will add a two dose vaccination program for women aged 9-14, providing more economical and convenient health protection for more eligible women, helping them stay away from HPV infection related cervical cancer and cervical lesions.